The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
Which emerging drivers are set to accelerate the growth of the colorectal cancer molecular diagnostics market further?
The increasing incidence of inflammatory bowel diseases (IBD) is expected to propel the growth of the colorectal cancer molecular diagnostic market going forward. Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders characterized by digestive tract inflammation, primarily affecting the colon and rectum, with symptoms like abdominal pain, diarrhea, and weight loss, managed through medications, lifestyle changes, and sometimes surgery. The increasing incidence of inflammatory bowel diseases fuels the demand for accurate, efficient, and advanced diagnostic solutions that play an essential role, as the determination of systemic therapy for colorectal cancer (CRC) predominantly relies on the result obtained from molecular assessment of the tumor For instance, in April 2024 according to the UK Parliament a UK-based Governing body In 2022, research by Crohn’s & Colitis UK found that 500,000 people in the UK live with Inflammatory Bowel Disease (IBD), nearly double previous estimates. Therefore, increasing incidences of inflammatory bowel diseases (IBD) will drive the growth of the colorectal cancer molecular diagnostic market.
Colorectal Cancer Molecular Diagnostics Market Driver: The Impact Of Increasing Colorectal Cancer Prevalence On The Colorectal Cancer Molecular Diagnostics Market
The rising prevalence of colorectal cancer is expected to propel the growth of the colorectal cancer molecular diagnostics market going forward. Colorectal cancer is a disease that affects the colon or rectum, which are parts of the digestive system. Colorectal cancer occurs when cells in the colon or rectum grow out of control and form a tumor. The increase in colorectal cancer increases the demand for molecular diagnostics for cancer detection and treatment. For instance, in March 2023, according to the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, roughly 153,020 people are expected to receive a diagnosis of CRC (colorectal cancer), and out of that number, approximately 52,550 individuals are projected to succumb to the disease. Among those affected, there will be 19,550 cases and 3,750 deaths occurring in individuals under the age of 50. Therefore, the rising prevalence of colorectal cancer is driving the growth of the colorectal cancer molecular diagnostics market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp
What are the key factors influencing the forecasted market size of the colorectal cancer molecular diagnostics industry?
The colorectal cancer molecular diagnostics market size has grown strongly in recent years. It will grow from $2.56 billion in 2024 to $2.77 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing incidence of colorectal cancer, growing awareness, and screening initiatives, rising emphasis on personalized medicine, government initiatives for cancer control.
The colorectal cancer molecular diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.79 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to aging population and increased risk factors, integration of genomic data into clinical practice, rise in precision medicine approaches, global efforts in cancer research and collaboration. Major trends in the forecast period include increasing emphasis on early detection biomarkers, integration of artificial intelligence (ai) in data analysis, rise of circulating tumor DNA (CTDNA) analysis, expansion of companion diagnostics for targeted therapies, focus on immunotherapy biomarkers.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp
Who are the leading competitors in the colorectal cancer molecular diagnostics market?
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.
Which emerging trends are set to transform the colorectal cancer molecular diagnostics market landscape?
Major companies operating in the colorectal cancer molecular diagnostic market focus on developing innovative molecular diagnostics and personalized medicine solutions, such as the shield blood test approach to identify colorectal cancer at an earlier, more treatable stage. Shield Blood Test, an initial blood test designed to identify early-stage colorectal cancer (CRC). For instance, in May 2022, Guardant Health, a US-based biotechnology company offering oncology molecular diagnostic products, launched its Shield Blood Test. The susceptible shield test provides a convenient screening option that involves a simple blood draw to address challenges related to patients’ willingness to get screened. The test showed a sensitivity of 91% for detecting colorectal cancer and 20% for detecting advanced adenomas, and the specificity was measured at 92%. The Shield test identifies early colorectal cancer signals in the blood by utilizing data from diverse cohorts of over 2,000 subjects with colorectal cancer, 357 with advanced adenoma, and 3,757 normal subjects.
How do different geographies compare in terms of market share and growth potential in the colorectal cancer molecular diagnostics market?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
Which major segments of the colorectal cancer molecular diagnostics market are experiencing the fastest growth?
The colorectal cancer molecular diagnostics market covered in this report is segmented –
1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings
Subsegments:
1) By Instruments: PCR Machines, Sequencers, Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs
3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120
How is the colorectal cancer molecular diagnostics market defined?
Colorectal cancer, also known as colon cancer or rectal cancer, is a malignant tumor that develops in the colon (the large intestine) or the rectum (the final portion of the digestive tract just before the anus). It is a type of cancer that arises from the inner lining of these parts of the gastrointestinal system. Colorectal cancer molecular diagnostics uses advanced techniques to identify specific genetic mutations, alterations, and biomarkers that play a role in the development, progression, and treatment response of colorectal cancer.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
